Thus, in MYCN-amplified NB cells expressing ALKF1174L, crizotinib effectively downregulated mTORC2 and PI3K, but had no appreciable inhibitory effect on mTORC1 activity. This evidence concerns the gene MYCN and neuroblastoma.